Two abstracts presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting explored the health-related quality of life (QOL) and mental health impact of psoriasis disease burden by severity and affected body region.
The health-related quality of life (HRQOL) impact of psoriasis was shown to be associated with severity of disease and location of lesion manifestations, according to findings of 2 abstracts presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting.
As the prevalence, incidence, and morbidity of psoriasis has risen over the last 3 decades, prior research investigated the growing discussion regarding mental health and QOL in patients.
Patients with psoriasis have been shown to be at a heightened risk of depression and adverse behavioral health symptoms, in which comorbidities such as psoriatic arthritis and disease severity have been shown to exacerbate risk. The incidence of psoriasis in special areas (face, scalp, palms/soles, nails, genitals) was noted by researchers to also potentially increase disease burden.
Leveraging the multinational UPLIFT survey, a web-based survey of adults with self-reported health care provider–diagnosed psoriasis that was conducted from March 2 to June 3, 2020, they evaluated the impact of special area involvement on QOL outcomes and depression screening.1
A total of 3614 patients with psoriasis who did and did not have special area involvement were compared via Dermatology Life Quality Index (DLQI) total score and Patient Health Questionnaire-2 (PHQ-2) depression screen measurements.
Of the study cohort, 76.8% (n = 2776) had psoriasis in att least 1 special area (face, 28.1%; scalp, 53.4%; palms/soles, 24.6%; nails, 16.7%; genitals, 12.2%).
Compared with patients without special area involvement, the mean (SD) DLQI scores were shown to be higher in patients who had psoriasis in 1 or more special areas overall (9.9 [8.5] vs 7.3 [7.3]). DLQI scores were shown to be highest for those with psoriasis in the face (12.4 [8.9]), palms/soles (11.7 [9.0]), and genitals (11.7 [9.0]), followed by nails (11.6 [9.1]) and scalp (9.5 [8.4]).
Patients with involvement in 1 or more special areas were also more likely than those without special area involvement to report that their psoriasis had at least a moderate effect on QOL (DLQI ≥ 6; 57.9% vs 47.5%) and to have a positive depression screen (PHQ-2 ≥ 3; 53.2% vs 44.1%).
A greater proportion of patients with psoriasis in 1 or more special areas (43.3%) had a DLQI scores of 6 or above and PHQ-2 of 3 or higher vs patients without special area involvement (32.8%).
“Results of the UPLIFT survey underscore the additional QOL and psychological burdens of psoriasis for patients with special area involvement vs those without involvement in special areas,” concluded the researchers.
The HRQOL impact on patients with psoriasis was further investigated by another analysis that assessed how improvements in Psoriasis Area and Severity Index (PASI) were associated with the achievement of DLQI 0/1 (no impact of skin disease on patient’s life).2
Pooled data from the initial 16-week periods of the BE SURE, BE VIVID, BE READY, and BE RADIANT phase 3/3b trials evaluating the use of several biologics in plaque psoriasis was included in the analyses.
Analyses included 2223 randomized patients with psoriasis who presented with a mean baseline PASI of 20.4 and a mean baseline DLQI of 10.7 (bimekizumab, n = 1362; placebo, n = 169; ustekinumab, n = 163; adalimumab, n = 159; secukinumab, n = 370).
Findings indicated that incremental PASI improvements translated to higher rates of patients achieving DLQI 0/1:
“These data highlight the importance of complete skin clearance for patients with plaque psoriasis and suggest that for patients who respond to treatment, but do not achieve complete skin clearance, residual disease may still negatively impact HRQOL,” said the researchers.
References
1. Langley RG, Augustin M, McBride S, et al. Impact of psoriasis in special areas on patient quality-of-life outcomes and depression screening: Findings from the multinational UPLIFT survey. Presented at: 2022 American Academy of Dermatology Annual Meeting; March 25-29; Boston, MA. Abstract 33950.
2. Blauvelt A, Lebwohl M, Gottlieb A, et al. Complete skin clearance for patients with moderate to severe plaque psoriasis: The relationship between improvements in Psoriasis Area and Severity Index and health-related quality of life. Presented at: 2022 American Academy of Dermatology Annual Meeting; March 25-29; Boston, MA. Abstract 33884.
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More
Patients With Advanced, Recurrent Melanoma May Experience Lasting AEs From ICM Therapy
May 9th 2024A cross-sectional, mixed-methods study found that adverse effects (AEs) can occur even after 1 year of treatment with immune checkpoint modulator (ICM) therapy in patients with melanoma.
Read More